OncoMatch/Clinical Trials/NCT06940297
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Is NCT06940297 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for recurrent multiple myeloma.
Treatment: Ciltacabtagene Autoleucel · Cyclophosphamide · Dasatinib · Fludarabine · Quercetin — This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
at least 3 prior lines of therapies including a proteasome inhibitor
Must have received: immunomodulatory drug
at least 3 prior lines of therapies including a...immunomodulatory drug (IMiD)
Must have received: anti-CD38 monoclonal antibody
at least 3 prior lines of therapies including a...anti-CD38 monoclonal antibody (mAb)
Cannot have received:
Exception: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 1 month since completion of prior treatment
Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL; ANC ≥ 1,000/mm^3; Platelet count ≥ 50,000/mm^3
Kidney function
Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's syndrome); ALT and AST ≤ 2 x ULN; Alkaline phosphatase ≤ 1.5 x ULN
Cardiac function
No evidence of current clinically significant uncontrolled arrhythmias, 2nd or 3rd degree AV block, recent MI/ACS/angioplasty/stenting/bypass (within 3 months), NYHA class III/IV heart failure, uncontrolled hypertension, history of life-threatening ventricular arrhythmias, QTC interval ≥ 450 msec
Hemoglobin ≥ 8.0 g/dL...; ANC ≥ 1,000/mm^3...; Platelet count ≥ 50,000/mm^3...; Total bilirubin ≤ 1.5 x ULN...; ALT and AST ≤ 2 x ULN...; Alkaline phosphatase ≤ 1.5 x ULN...; Calculated creatinine clearance ≥ 30 ml/min...; Evidence of cardiovascular disease risk, as defined by any of the following:... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify